David E Leaf

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1377214/publications.pdf

Version: 2024-02-01

126 papers	10,999 citations	53794 45 h-index	33894 99 g-index
127 all docs	127 docs citations	127 times ranked	16553 citing authors

#	Article	IF	Citations
1	Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. American Journal of Kidney Diseases, 2022, 79, 134-137.	1.9	20
2	Kidney Recovery and Death in Critically Ill Patients With COVID-19â€“Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. American Journal of Kidney Diseases, 2022, 79, 404-416.e1.	1.9	23
3	Association of Surge Conditions with Mortality Among Critically Ill Patients with COVID-19. Journal of Intensive Care Medicine, 2022, 37, 500-509.	2.8	8
4	Controlled Study of Decision-Making Algorithms for Kidney Replacement Therapy Initiation in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 194-204.	4.5	2
5	Hispanic ethnicity and mortality among critically ill patients with COVID-19. PLoS ONE, 2022, 17, e0268022.	2.5	11
6	Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1510-1518.	0.8	19
7	Outcomes of Critically Ill Pregnant Women with COVID-19 in the United States. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 122-125.	5.6	17
8	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 41.	5.1	385
9	Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. American Journal of Kidney Diseases, 2021, 77, 190-203.e1.	1.9	167
10	AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2021, 32, 161-176.	6.1	207
11	Response to â€œIs the outcome of SARSâ€CoVâ€2 infection in solid organ transplant recipients really similar to that of the general population?â€• American Journal of Transplantation, 2021, 21, 1672-1673.	4.7	0
12	Tocilizumab in Covid-19. New England Journal of Medicine, 2021, 384, 86-87.	27.0	25
13	Acute kidney injury in renal transplant recipients undergoing cardiac surgery. Nephrology Dialysis Transplantation, 2021, 36, 185-196.	0.7	7
14	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Medicine, 2021, 47, 208-221.	8.2	143
15	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e500-e511.	0.9	35
16	Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019â€“Related Respiratory Failure*. Critical Care Medicine, 2021, 49, 1026-1037.	0.9	64
17	Questioning the Futility of Cardiopulmonary Resuscitation in Patients With Severe Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e795-e796.	0.9	1
18	Histopathologic Correlates of Kidney Function: Insights From Nephrectomy Specimens. American Journal of Kidney Diseases, 2021, 77, 336-345.	1.9	17

#	Article	IF	Citations
19	A Systematic Review of the Incidence and Outcomes of In-Hospital Cardiac Arrests in Patients With Coronavirus Disease 2019*. Critical Care Medicine, 2021, 49, 901-911.	0.9	11
20	Vitamin D₃ to Treat COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1047.	7.4	30
21	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	27.0	1,419
22	Tissue Plasminogen Activator in Critically Ill Adults with COVID-19. Annals of the American Thoracic Society, 2021, 18, 1917-1921.	3.2	11
23	Diphenhydramine for the prevention of cisplatin-associated acute kidney injury. Kidney International, 2021, 99, 1025-1026.	5.2	2
24	Tocilizumab in COVID-19: some clarity amid controversy. Lancet, The, 2021, 397, 1599-1601.	13.7	29
25	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. Annals of Internal Medicine, 2021, 174, 622-632.	3.9	89
26	Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. American Journal of Kidney Diseases, 2021, 77, 990-992.	1.9	18
27	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
28	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	8.2	65
29	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.	5.2	95
30	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
31	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 403-411.	5.6	39
32	Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019. , 2021, 3, e0515.		12
33	Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVIDâ€19 in the US. Obesity, 2021, 29, 1719-1730.	3.0	11
34	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
35	Severe autoimmune hemolytic anemia following receipt of <scp>SARSâ€CoV</scp>â€2 <scp>mRNA</scp> vaccine. Transfusion, 2021, 61, 3267-3271.	1.6	29
36	Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States. Cell Reports Medicine, 2021, 2, 100376.	6.5	8

#	Article	IF	Citations
37	Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest, 2021, 160, 929-943.	0.8	31
38	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 157, 50-58.	2.8	9
39	Intraoperative Oxygen Concentration and Neurocognition after Cardiac Surgery. Anesthesiology, 2021, 134, 189-201.	2.5	31
40	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
41	Effect of Convalescent Plasma on Organ Supportâ€"Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
42	Protocol to assess performance of crisis standards of care guidelines for clinical triage. STAR Protocols, 2021, 2, 100943.	1.2	1
43	Sex-related differences in mortality, acute kidney injury, and respiratory failure among critically ill patients with COVID-19. Medicine (United States), 2021, 100, e28302.	1.0	8
44	High Prevalence of Imposterism Among Female Harvard Medical and Dental Students. Journal of General Internal Medicine, 2020, 35, 2499-2501.	2.6	24
45	In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ, The, 2020, 371, m3513.	6.0	108
46	Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Internal Medicine, 2020, 180, 1436.	5.1	711
47	Acute Kidney Injury Following Paracentesis Among Inpatients With Cirrhosis. Kidney International Reports, 2020, 5, 1305-1308.	0.8	3
48	Short Bowel Syndrome and Kidney Transplantation: Challenges, Outcomes, and the Use of Teduglutide. Case Reports in Transplantation, 2020, 2020, 1-5.	0.3	0
49	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney International Reports, 2020, 5, 1700-1705.	0.8	47
50	Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. American Journal of Transplantation, 2020, 20, 3061-3071.	4.7	89
51	The Macrophage Migration Inhibitory Factor (MIF) Promoter Polymorphisms (rs3063368, rs755622) Predict Acute Kidney Injury and Death after Cardiac Surgery. Journal of Clinical Medicine, 2020, 9, 2936.	2.4	9
52	Dexamethasone for Preventing Major Adverse Kidney Events following Cardiac Surgery: Post-Hoc Analysis to Identify Subgroups. Kidney360, 2020, 1, 530-533.	2.1	1
53	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020, 136, 489-500.	1.4	1,021
54	Erythropoietin, Fibroblast Growth Factor 23, and Death After Kidney Transplantation. Journal of Clinical Medicine, 2020, 9, 1737.	2.4	0

#	Article	IF	Citations
55	ABO phenotype and death in critically ill patients with COVIDâ€19. British Journal of Haematology, 2020, 190, e204-e208.	2.5	62
56	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.	2.1	62
57	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. American Journal of Kidney Diseases, 2020, 76, 63-71.	1.9	74
58	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	27.0	149
59	Clinical Features and Outcomes of Immune Checkpoint Inhibitorâ€"Associated AKI: A Multicenter Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 435-446.	6.1	247
60	Peritoneal dialysate tamponading a massive retroperitoneal hemorrhage. Kidney International, 2020, 97, 810.	5.2	1
61	Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-Î³ in NK cells. Journal of Clinical Investigation, 2020, 130, 3238-3252.	8.2	52
62	Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. Journal of Clinical Investigation, 2020, 130, 1513-1526.	8.2	75
63	IDEAL-ICU in Context. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1264-1267.	4.5	5
64	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1692-1700.	4.5	193
65	A case of severe hypothyroidism due to lenalidomide. Clinical Case Reports (discontinued), 2019, 7, 1747-1749.	0.5	0
66	Prevention of Cardiac Surgery-Associated Acute Kidney Injury. Anesthesiology Clinics, 2019, 37, 729-749.	1.4	8
67	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Medicine, 2019, 16, e1002818.	8.4	16
68	Uric Acid and Acute Kidney Injury in the Critically Ill. Kidney Medicine, 2019, 1, 21-30.	2.0	6
69	Iron, Hepcidin, and Death in Human AKI. Journal of the American Society of Nephrology: JASN, 2019, 30, 493-504.	6.1	41
70	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	4.1	51
71	Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention. Journal of the American Society of Nephrology: JASN, 2019, 30, 2060-2071.	6.1	35
72	Secretory Leukocyte Protease Inhibitor (SLPI)â€"A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study. Journal of Clinical Medicine, 2019, 8, 1931.	2.4	22

#	Article	IF	Citations
73	Dysregulated Mineral Metabolism in AKI. Seminars in Nephrology, 2019, 39, 41-56.	1.6	38
74	Fibroblast Growth Factor 23 and Klotho in AKI. Seminars in Nephrology, 2019, 39, 57-75.	1.6	50
75	Introduction: Cross-Talk Between the Kidneys and Remote Organ Systems in AKI. Seminars in Nephrology, 2019, 39, 1-2.	1.6	5
76	Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 531-541.	4.5	43
77	Acute blood loss stimulates fibroblast growth factor 23 production. American Journal of Physiology - Renal Physiology, 2018, 314, F132-F139.	2.7	52
78	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2344-2353.	2.0	37
79	De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nature Medicine, 2018, 24, 1351-1359.	30.7	250
80	Risk Prediction Models for Acute Kidney Injury in Critically Ill Patients: Opus in Progressu. Nephron, 2018, 140, 99-104.	1.8	22
81	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018, 132, 1037-1037.	1.4	1
82	Autoimmune hemolytic anemia in a young man with acute hepatitis E infection. American Journal of Hematology, 2017, 92, E77-E79.	4.1	14
83	Characterization of Population of HSCT Associated Thrombotic Microangiopathy (TMA). Biology of Blood and Marrow Transplantation, 2017, 23, S292-S293.	2.0	1
84	Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. BMC Nephrology, 2017, 18, 44.	1.8	21
85	Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. Journal of the American Society of Nephrology: JASN, 2017, 28, 1877-1885.	6.1	76
86	C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 3639-3646.	6.1	46
87	BPI Fold-Containing Family A Member 2/Parotid Secretory Protein Is an Early Biomarker of AKI. Journal of the American Society of Nephrology: JASN, 2017, 28, 3473-3478.	6.1	24
88	A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 482-490.	5.6	31
89	End Points for Clinical Trials in Acute Kidney Injury. American Journal of Kidney Diseases, 2017, 69, 108-116.	1.9	16
90	Stability of Fibroblast Growth Factor 23 in Human Plasma. journal of applied laboratory medicine, The, 2017, 1, 729-734.	1.3	9

#	Article	IF	Citations
91	Clinical predictors of diagnostic testing utility in the initial evaluation of chronic kidney disease. Nephrology, 2016, 21, 851-859.	1.6	6
92	An electronic alert to decrease Kayexalate ordering. Renal Failure, 2016, 38, 1752-1754.	2.1	6
93	Catalytic iron and acute kidney injury. American Journal of Physiology - Renal Physiology, 2016, 311, F871-F876.	2.7	32
94	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney International, 2016, 90, 638-647.	5.2	524
95	Excessive diagnostic testing in acute kidney injury. BMC Nephrology, 2016, 17, 9.	1.8	15
96	Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2016, 27, 3291-3297.	6.1	39
97	Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney International, 2016, 89, 939-948.	5.2	71
98	Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery. Kidney International, 2015, 87, 1046-1054.	5.2	61
99	Intraoperative High-Dose Dexamethasone and Severe AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2015, 26, 2947-2951.	6.1	78
100	Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Critical Care, 2015, 19, 80.	5.8	33
101	The Usefulness of Diagnostic Testing in the Initial Evaluation of Chronic Kidney Disease. JAMA Internal Medicine, 2015, 175, 853.	5.1	11
102	Plasma Catalytic Iron, AKI, and Death among Critically Ill Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1849-1856.	4.5	34
103	Reply: Active and Native Vitamin D in Critical Illness. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1194-1196.	5.6	0
104	Implementation of a CKD Checklist for Primary Care Providers. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1526-1535.	4.5	44
105	Patient Visibility and ICU Mortality: A Conceptual Replication. Herd, 2014, 7, 92-103.	1.5	43
106	Randomized Controlled Trial of Calcitriol in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 533-541.	5.6	121
107	Rosuvastatin for Sepsis-Associated ARDS. New England Journal of Medicine, 2014, 371, 968-969.	27.0	6
108	Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney International, 2013, 84, 776-785.	5.2	147

#	Article	IF	Citations
109	A Physiologicâ€“Based Approach to the Evaluation of a Patient With Hyperphosphatemia. American Journal of Kidney Diseases, 2013, 61, 330-336.	1.9	7
110	Chloride-liberal fluids and intracellular acidosis. Kidney International, 2013, 83, 971.	5.2	0
111	Oncogenic Osteomalacia due to FGF23-Expressing Colon Adenocarcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 887-891.	3.6	73
112	Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clinical Endocrinology, 2013, 79, 491-498.	2.4	64
113	Colpocephaly in adults. BMJ Case Reports, 2013, 2013, bcr2013009505-bcr2013009505.	0.5	10
114	Effect of Vitamin D Repletion on Urinary Calcium Excretion among Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 829-834.	4.5	68
115	FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1217-1223.	4.5	74
116	Laxative Abuse, Eating Disorders, and Kidney Stones: A Case Report and Review of the Literature. American Journal of Kidney Diseases, 2012, 60, 295-298.	1.9	18
117	Impact of Nonphysician Staffing on Outcomes in a Medical ICU. Chest, 2011, 139, 1347-1353.	0.8	113
118	Relationship Between ICU Design and Mortality. Chest, 2010, 137, 1022-1027.	0.8	58
119	A Severe Case of Cefoxitin-Induced Immune Hemolytic Anemia. Acta Haematologica, 2010, 124, 197-199.	1.4	4
120	Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. Nephrology Dialysis Transplantation, 2010, 25, 1335-1337.	0.7	29
121	Calcium Kidney Stones. New England Journal of Medicine, 2010, 363, 2470-2471.	27.0	4
122	Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney International, 2010, 78, 337-342.	5.2	36
123	Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney International, 2009, 75, 15-24.	5.2	124
124	SOMOSAT: Utility of a web-based self-assessment tool in undergraduate medical education. Medical Teacher, 2009, 31, e211-e219.	1.8	8
125	Connexin40 Imparts Conduction Heterogeneity to Atrial Tissue. Circulation Research, 2008, 103, 1001-1008.	4.5	53
126	Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. Journal of Applied Physiology, 2007, 102, 1313-1322.	2.5	172